NICE Rejects Tecentriq For Small-Cell Lung Cancer In England

Uncertainties Remain Over Long-Term Effectiveness

Roche’s Tecentriq has been rejected by health technology assessment body NICE for use in small-cell lung cancer on the National Health Service. The move follows an earlier knockback for the drug in PD L1-positive triple-negative breast cancer.

NICE, the health technology appraisal body for England, has rejected Roche’s Tecentriq (atezolizumab) for small-cell lung cancer, saying there are uncertainties over the duration of the treatment effect and overall survival and that the treatment does not represent a cost-effective use of National Health Service resources.

The recommendation Roche had sought was for routine NHS funding of Tecentriq in combination with carboplatin and etoposide for untreated...